Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24K | -16K | -79K | -447K | -32K |
| EBITDA | -24K | -16K | -79K | -447K | -32K |
| Net Income | -24K | -16K | -79K | 0 | -32K |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$0.0001
+0.00% today
1Y Change
-99.98%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanrong Biotechnology Corp. (SRBT) is a Financial Services stock with listed on OTC. The stock last traded around $0.00 and down 100.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -43.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -43.5%, free cash flow 0.0% with operating margin 0.0% and ROIC 93.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRBT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRBT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRBT Max Drawdown
-99.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRBT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$31.8K
Free Cash Flow
$0.0
Revenue Growth
+0.0%
EPS Growth
-43.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24K | -16K | -79K | -447K | -32K |
| EBITDA | -24K | -16K | -79K | -447K | -32K |
| Net Income | -24K | -16K | -79K | 0 | -32K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2K | 18K | 0 | 25K | 0 |
| Total Assets | 2K | 18K | 0 | 25K | 0 |
| Total Liabilities | 662K | 97K | 0 | 64K | 7K |
| Shareholder Equity | -660K | -77K | 3K | -39K | -7K |
| Total Debt | 0 | 0 | 0 | 0 | 525 |
| Net Debt | -2K | -18K | 0 | -25K | 525 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
0
Capital Expenditures
0
Free Cash Flow
0
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
6.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.